SormaniMPBruzziP.MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomized trials. Lancet Neurol2013; 12: 669–676.
2.
SalvettiMLandesmanDSchwarz-LamPet al. Progressive MS: From pathophysiology to drug discovery. Mult Scler2015; 21: 1376–1384.
3.
HulstHEThompsonAJGeurtsJJG. The measure tells the tale: Clinical outcome measures in multiple sclerosis. Mult Scler2017; 23: 626–627.
4.
GiovannoniGCutterGSormaniMPet al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord2017; 12: 70–78.
5.
FreemanLGarcia-LorenzoDBottinLet al. The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study. Ann Neurol2015; 78: 554–567.
6.
PolitisMGiannettiPSuPet al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology2012; 79: 523–530.
7.
WangYSunPWangQet al. Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis. Brain2015; 138: 1223–1238.
8.
MaineroCLouapreCGovindarajanSTet al. A gradient of cortical pathology in multiple sclerosis by in vivo quantitative 7T imaging. Brain2015; 138: 932–945.
9.
PetraccaMVanceaROFleyscherLet al. Brain intra- and extracellular sodium concentration in multiple sclerosis: A 7T MRI study. Brain2016; 139: 795–806.
10.
TomassiniVMatthewsPMThompsonAJet al. Neuroplasticity and functional recovery in multiple sclerosis. Nature Rev Neurol2012; 8: 635–646.
11.
GassARoccaMAAgostaFet al. MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. Lancet Neurol2015; 14: 443–454.
